SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
SYnAbs mouse anti-rat light chains to monitore immune isotypic response, quantify circulating rat therapeutic antibody candidates, and easily purify all rat isotypes without cross-binding to bovine serum immunoglobulins
SYnAbs rat anti-mouse IgG to monitore immune isotypic response to infections and vaccines, better comprehend B-cells & T-cells interactions and pathology-related mechanisms in transgenic mouse models
SYnAbs unique highly specific anti-human IgG4 monoclonal antibodies without cross-reaction to the other human isotypes subclasses IgG1, IgG2, and IgG3.
SYnAbs unique therapeutic rat monoclonal antibodies targeting CD2 giving birth to Siplizumab and LO-CD2b for T cell depletion. Unique DNA, syngeneic cell immunization strategies to generate monoclonals against transmembrane proteins.
Benefit from natural in-vivo maturation to get access to highly specific and high affinity rat monoclonal antibodies for therapeutic use targeting transmembrane proteins GPCR, ion channels and other complex epitopes